
|Videos|May 9, 2014
Dutasteride for the Treatment of Prostate Cancer
Author(s)Rana R. McKay, MD
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses the mechanism of action of dutasteride and its role in a phase II prostate cancer trial.
Advertisement
Clinical Pearls
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses the mechanism of action of dutasteride and its role in a phase II prostate cancer trial.
- Dutasteride is a dual 5-α reductase inhibitor that prevents the conversion of testosterone to DHT. It is classically used for people with benign prostatic hypertrophy.
- In a phase II trial, dutasteride was combined with abiraterone acetate for the treatment of metastatic castration resistant prostate cancer.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
4
Early Relapse Guides Use of CAR T vs Other Options in LBCL
5








































